

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. – 22. (Cancelled)

23. (Currently Amended) ~~A pharmaceutical~~ An immunogenic composition comprising a pharmaceutically acceptable carrier, diluent or adjuvant and an isolated polypeptide that consists of an amino acid sequence at least 90% identical to the full-length amino acid sequence set forth as SEQ ID NO:2, wherein the isolated polypeptide elicits an antibody that specifically binds to a polypeptide that consists of the amino acid sequence set forth as SEQ ID NO:2, and wherein the isolated polypeptide induces an immune response against *Streptococcus pyogenes*.

24. - 35. (Cancelled)

36. (Previously Presented) A kit comprising an isolated polypeptide for detection or diagnosis of *Streptococcus pyogenes* infection, wherein the isolated polypeptide is selected from (a) an isolated polypeptide that consists of an amino acid sequence at least 90% identical to the full-length amino acid sequence set forth as SEQ ID NO:2; (b) an isolated polypeptide that comprises an amino acid sequence at least 95% identical to the full-length amino acid sequence set forth as SEQ ID NO:2; and (c) an isolated polypeptide that comprises the amino acid sequence set forth as SEQ ID NO:2, wherein the isolated polypeptide is capable of eliciting an antibody that specifically binds to a polypeptide consisting of the amino acid sequence set forth as SEQ ID NO:2.

37. (Cancelled)

38. (Currently Amended) The ~~pharmaceutical-immunogenic~~ composition of claim 23 wherein the isolated polypeptide consists of an amino acid sequence at least 95% identical to the full-length amino acid sequence set forth as SEQ ID NO:2.

39. (Currently Amended) The ~~pharmaceutical-immunogenic~~ composition of claim 23 wherein the isolated polypeptide consists of the amino acid sequence set forth as SEQ ID NO:2.

40. (Currently Amended) ~~A pharmaceutical~~An immunogenic composition comprising a pharmaceutically acceptable carrier, diluent or adjuvant and an isolated polypeptide that comprises an amino acid sequence at least 95% identical to the full-length amino acid sequence set forth as SEQ ID NO:2, wherein the isolated polypeptide elicits an antibody that specifically binds to a polypeptide that consists of the amino acid sequence set forth as SEQ ID NO:2, and wherein the isolated polypeptide induces an immune response against *Streptococcus pyogenes*.

41. (Currently Amended) The ~~pharmaceutical-immunogenic~~ composition of claim 40 wherein the isolated polypeptide comprises the amino acid sequence set forth as SEQ ID NO:2.

42. (Currently Amended) ~~A chimeric~~An immunogenic composition comprising (1) a pharmaceutically acceptable carrier, diluent or adjuvant and (2) an isolated polypeptide ~~comprising that comprises~~ an antigenic fragment that consists of at least 15 contiguous amino acids of SEQ ID NO:2, and wherein the antigenic fragment elicits an antibody that specifically binds to a polypeptide that consists of the amino acid sequence set forth as SEQ ID NO:2, and wherein the antigenic fragment induces an immune response against *Streptococcus pyogenes*.

43. – 48. (Cancelled)